Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Stereoisomerism of Cyclic Compounds

Stereoisomerism of Cyclic Compounds

In this lesson, we delve into the role of ring conformation and its stability, which determines the spatial arrangement and, consequently, the molecular symmetry and stereoisomerism of cyclic compounds. 1,2-Dimethylcyclohexane is used as a case study to evaluate the possible number of stereoisomers. Here, given the multiple (n = 2) chiral centers, there are 2n = 4 possible configurations that lack a plane of symmetry, as the ring skeleton exists in a non-planar chair conformation. In addition,...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Porous Ni-based metal-organic frameworks reduce the oxygen evolution temperature of lithium perchlorate.

Dalton transactions (Cambridge, England : 2003)·2026

Same author

Quantum Coherence in a Perylene-Based Metal-Organic Framework for Potential Solid-State Qubits.

Journal of the American Chemical Society·2026

Same author

Reversible color switching of bright phosphorescence in purely organic materials for advanced data encryption.

Nature communications·2026

Same author

Transitioning Formamide Solvothermal Syntheses of MOFs to Less Toxic Solvents.

Chemistry (Weinheim an der Bergstrasse, Germany)·2025

Same author

Elucidating the molecular structural origin of efficient emission across solid and solution phases of single benzene fluorophores.

Nature communications·2025

Same author

Selecting a laser excitation source and sampling strategy for Raman spectroscopy.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2025

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Coherent anti-Stokes Raman Scattering (CARS) Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Coherent anti-Stokes Raman Scattering (CARS) Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Published on: July 4, 2014

Polymorphism in Carbamazepine Cocrystals.

William W Porter¹, Sophia C Elie, Adam J Matzger

¹Department of Chemistry and the Macromolecular Science and Engineering Program, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan 48109-1055.

Crystal Growth & Design

|September 28, 2011

Summary

This summary is machine-generated.

Polymorphism in carbamazepine cocrystals was investigated. New polymorphs of carbamazepine-nicotinamide (CBZ-NCT) and carbamazepine-saccharin (CBZ-SAC) cocrystals were identified, revealing unique structural features.

More Related Videos

$Microcrystal Electron Diffraction of Small Molecules$

Microcrystal Electron Diffraction of Small Molecules

Published on: March 15, 2021

Crystallization of Membrane Proteins in Lipidic Mesophases

Crystallization of Membrane Proteins in Lipidic Mesophases

Published on: March 28, 2011

Related Experiment Videos

Last Updated: Jun 24, 2026

Coherent anti-Stokes Raman Scattering (CARS) Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Coherent anti-Stokes Raman Scattering (CARS) Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Published on: July 4, 2014

$Microcrystal Electron Diffraction of Small Molecules$

Microcrystal Electron Diffraction of Small Molecules

Published on: March 15, 2021

Crystallization of Membrane Proteins in Lipidic Mesophases

Crystallization of Membrane Proteins in Lipidic Mesophases

Published on: March 28, 2011

Area of Science:

Crystallography
Materials Science
Pharmaceutical Science

Background:

Carbamazepine (CBZ) cocrystals are widely studied for drug formulation.
Polymorphism significantly impacts pharmaceutical properties.
Understanding cocrystal polymorphs is crucial for drug development.

Purpose of the Study:

To investigate the polymorphism of carbamazepine-nicotinamide (CBZ-NCT) and carbamazepine-saccharin (CBZ-SAC) cocrystals.
To characterize novel polymorphs using advanced analytical techniques.
To explore the role of polymer heteronuclei in cocrystal formation.

Main Methods:

Cocrystal synthesis via solution growth in the presence of polymer heteronuclei.
Characterization using Raman spectroscopy and powder X-ray diffraction (PXRD).
Single-crystal X-ray diffraction for structural determination of new polymorphs.

Main Results:

Two polymorphs of CBZ-NCT cocrystals were identified: CBZ-NCT I and a polymer-nucleated (PN) form.
A new polymorph of CBZ-SAC, designated CBZ-SAC II, was discovered.
CBZ-SAC II crystallizes in the monoclinic space group C2/c, exhibiting a distinct heterosynthon formation between carbamazepine and saccharin.

Conclusions:

Carbamazepine-nicotinamide and carbamazepine-saccharin cocrystals exhibit polymorphism.
Polymer heteronuclei can influence the formation of specific cocrystal polymorphs.
The discovery of new polymorphs, particularly CBZ-SAC II with its unique heterosynthon, expands the understanding of carbamazepine cocrystal behavior.